Pharma

Pharma Meghana Keshavan

STAT Plus: Pfizer’s abrupt withdrawal of sickle cell drug Oxbryta called ‘tone deaf’ at ASH conference

Politics John Wilkerson

STAT Plus: BIOSECURE Act, aimed at Chinese drug manufacturers, is dealt a major blow

Pharma Adam Feuerstein and Jonathan Wosen

STAT Plus: Sanofi advances a drug for a rare, platelet-destroying disease

Pharmalot Ed Silverman

STAT Plus: European regulators approve $16.5 billion deal for Novo Holdings to buy Catalent

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about cracks in the MAHA alliance, pharmacies suing GoodRx and PBMs, and more

The Readout Meghana Keshavan

STAT Plus: Lilly’s $3 billion investment in Wisconsin

The Readout Meghana Keshavan

STAT Plus: AstraZeneca replaces benched exec in China

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about U.K. restricting Lilly’s obesity drug, pharma layoffs, and more

Health Andrew Joseph

STAT Plus: U.K. to restrict Eli Lilly’s obesity drug to patients with greatest need 

Pharmalot Ed Silverman

STAT Plus: U.S. Patent Office pulls controversial rule to curb pharma patent abuse

Pharmalot Andrew Joseph

STAT Plus: Pharmalittle: We’re reading about a Zepbound-Wegovy faceoff, compounders slamming Novo, and more

The Readout Meghana Keshavan

STAT Plus: Compounding pharmacies rebut Novo’s FDA petition

Health Tech Newsletter Mohana Ravindranath

STAT Plus: Pfizer, Eli Lilly execs push back as senators scrutinize drugmakers’ telehealth moves

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about menopause treatments, Novo plans for Wegovy in India, and more

The Readout Meghana Keshavan

STAT Plus: Sanofi pours $1 billion into China for insulin plant

The Readout Meghana Keshavan

STAT Plus: Despite probe, China reimbursing AstraZeneca drug

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a former Trump FDA chief criticizing RFK Jr., a radiopharmaceuticals talent shortage, and more

Pharmalot Ed Silverman

STAT Plus: Big restaurant chains get an ‘F’ for antibiotic use in their meat supplies

The Readout Meghana Keshavan

STAT Plus: The biotech news you need to read today

Pharmalot Ed Silverman

STAT Plus: Bristol Myers is the latest drug company to sue HHS over payment terms for 340B hospitals

Politics John Wilkerson

STAT Plus: It might be now or never for the BIOSECURE Act

Health Lizzy Lawrence

STAT Plus: Trump taps biotech investor Jim O’Neill for HHS deputy secretary

D.C. Diagnosis Sarah Owermohle

STAT Plus: Unpacking Trump’s latest picks for top health roles

The Readout Adam Feuerstein

STAT Plus: Roche’s TIGIT troubles continue, a novel Alzheimer’s target misses the mark, and other biotech news

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Medicare obesity drug coverage, a first-of-its-kind 340B analysis, and more

Pharma Alex Hogan

STAT Plus: Inside the telehealth-fueled GLP-1 alternative market

Pharma Andrew Joseph

STAT Plus: Roche immunotherapy fails in lung cancer study, raising questions about drug’s target

Pharmalot Ed Silverman

STAT Plus: Minnesota becomes first state to release report on 340B drug discount program for ‘safety-net’ hospitals